-
T-cell lymphoma new drug! Cinda BioPD-1 inhibitor Dabershu ® (Sindili mono-resistance) was granted the U.S. FDA's certification of orphan drugs!
Time of Update: 2020-03-30
March 30, 2020 / Biovalley BIOON/ -- Innovent Biologic is a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for the treatment of major diseases such
-
First-line immunotherapy for lung cancer! Ono Pharmaceuticals submits a first-line treatment NSCLC supplement arying opdivo-Yervoy-chemotherapy combination!
Time of Update: 2020-03-29
March 29, 2020 / Biovalley BIOON / -- Ono Pharmaceuticals and Bristol-Myer Squibb K.K., Japan, have jointly announced that they have submitted a supplementary application in Japan seeking approval
-
Improved TB vaccine is expected to prevent recurrence of bladder cancer
Time of Update: 2020-02-27
February 27, 2020 / BIOON / -- human immune system can not only recognize and kill bacteria, but also kill cancer cells That's why treatment with weak bacteria can help the immune system fight cancer
-
EGFR mutation lung cancer first-line treatment of new options! The combination therapy of cyramza and erlotinib was approved by FDA advisory committee!
Time of Update: 2020-02-27
February 27, 2020 / BIOON / -- Eli Lilly recently announced that the U.S Food and Drug Administration (FDA) cancer Based on the results of phase III study, the first-line treatment of EGFR mutation po
-
Clin Cancer Res: combined immunotherapy for advanced neuroendocrine cancer
Time of Update: 2020-02-26
February 26, 2020 / bioun / -- according to the results of a recent clinical trial targeting CTLA-4 and PD-1 to treat rare tumors (DART), many patients with severe symptoms of neuroendocrine tumors re
-
Major breakthrough! The role of nature focused B cells in antitumor immunotherapy
Time of Update: 2020-02-26
February 26, 2020 / Biovalley bio on / -- new research shows that there are "factories" full of immune cells lurking in the depths of some tumors, which can help the body fight against cancer and are
-
HER2 + breast cancer innovation! The combination of perjeta and Herceptin subcutaneous preparation of Roche fixed dose was accepted by FDA in the United States, and the administration only took 5-8 minutes
Time of Update: 2020-02-26
February 26, 2020 / BIOON / -- Roche recently announced that the U.S Food and Drug Administration (FDA) has accepted a biological product licensing application (BLA) submitted by it, which seeks to ap
-
Nat mate: break the rules! Reveal the new mechanism of nanoparticles into tumor!
Time of Update: 2020-02-24
February 24, 2020 / Biovalley / -- researchers from the University of Toronto found that it is the active process rather than the passive process that determines which nanoparticles enter the solid tu
-
Cancer cell: circular RNA limits the metastasis of skin cancer
Time of Update: 2020-02-24
February 24, 2020 / BIOON / - a new study found that a mysterious genetic material can inhibit the spread of skin cancer cells, but as they mature, the material is often lost The new study was recentl
-
Immunotherapy for esophageal cancer! Bosimer opdivo (odevo) received the first regulatory approval, regardless of PD-L1, which significantly extended the life span!
Time of Update: 2020-02-22
February 22, 2020 / BIOON / -- Bristol Myers Squibb (BMS) recently announced that MHLW (Ministry of health, labor and welfare) of Japan has approved the anti PD-1 therapy opdivo (odivo, common name: n
-
Bladder cancer "platinum free, targeted + immune" program! The combination of padcev + keytruda obtained the breakthrough drug qualification, and the total remission rate of first-line treatment was 73.3%
Time of Update: 2020-02-21
February 21, 2020 / BIOON / -- Seattle genetics and Astellas recently announced that the U.S Food and Drug Administration (FDA) has awarded the antibody drug conjugate (ADC) padcev (enfortumab) The co
-
First line immunotherapy for lung cancer! The treatment of PD-L1 overexpression NSCLC with single drug of Roche tecentriq was given priority review, and the survival period was significantly prolonged
Time of Update: 2020-02-20
February 20, 2020 / BIOON / -- Roche's gene tech recently announced that the U.S Food and Drug Administration (FDA) has accepted a supplementary biological product license application (SBLA) from tece
-
Target tumor "don't eat me" signal! Alx418, a CD47 checkpoint inhibitor, has obtained two FDA fast track qualifications to treat head and neck cancer and gastric cancer
Time of Update: 2020-02-20
February 20, 2020 news / BIOON / -- Alex oncology is a clinical stage immunooncology company, which is committed to developing innovative therapies to block the checkpoint mechanism of CD47 Cancer cel
-
Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors
Time of Update: 2020-02-20
February 20, 2020 / Biogen / -- oncogenic Ras mutant (rasmut) protein is unable to be contacted and targeted by conventional antibodies due to its position in the cell, so it is impossible to target t
-
Angelw Chem: Chinese scholars develop powerful new drugs for pancreatic cancer
Time of Update: 2020-02-20
February 20, 2020 news / Bio Valley bio on / -- pancreatic cancer is one of the most aggressive and fatal malignant tumors in human beings, with a very poor prognosis Therefore, more effective treatme
-
Turn "cold tumor" into "hot tumor"! The first Sema4D antibody pepinemab combined with bavencio in the treatment of lung cancer (NSCLC) has a strong effect!
Time of Update: 2020-02-19
February 19, 2020 / bioun / -- recently, the interim analysis of the clinical immunooncology Ib / II clinical trial (nct03268057) published by asco-sitc in Orlando showed that pepinemab (vx15 / 2503)
-
Muscle invasive bladder cancer (MIBC)! Prisimer opdivo combined with chemotherapy for neoadjuvant treatment, the complete remission rate (PCR) was 49%!
Time of Update: 2020-02-18
February 18, 2020 / BIOON / -- recently, a clinical trial of bladder cancer was announced at the 2020 American Society of clinical oncology urogenital cancer symposium (ASCO-GU 2020) held in San Franc
-
Immunotherapy for advanced renal cell carcinoma (RCC)! The 5-year survival rate of opdivo is 26%, and the curative effect is better than that of Everest!
Time of Update: 2020-02-17
February 17, 2020 / BIOON / -- BMS recently held ASCO-GU in San Francisco In 2020), the 5-year follow-up results of the phase III checkmate-025 study on the treatment of advanced renal cell carcinoma
-
First line treatment of renal cell carcinoma! The long-term effect of opdivo + yevoy is better than SUTENT, and the 42 month survival rate is more than 50%!
Time of Update: 2020-02-17
February 17, 2020 / BIOON / -- BMS recently held ASCO-GU in San Francisco In 2020), the latest results of the research on opdivo combined with low dose yevoy (ipilimumab, ipilimumab) in the first-line
-
New adjuvant therapy for bladder cancer (MIBC)! The pathological complete remission rate (PCR) of imfinzi + lynparza was 50%
Time of Update: 2020-02-17
February 17, 2020 / BIOON / -- recently, a single arm phase II study (nct03534492) published at the 2020 American Society of clinical oncology urogenital cancer symposium (ASCO-GU 2020) held in San Fr
